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Abstract
Since the discovery that  introduction of  four specific  genes encoding transcription
factors convert mature human somatic cells into induced pluripotent stem cells (iPSCs),
there has been an enormous increase in the applications of iPSC technologies to medical
sciences, especially in modeling human diseases. In this review, we summarize recent
advances in applying human iPSC reprogramming to generate patient-specific neural
subtypes in order to reveal molecular pathways affected in various neurodegenera‐
tive  diseases.  Metabolites  provide  a  functional  readout  of  various  cellular  states
enabling identification of  biomarker  candidates  for  early  diagnosis,  segregation of
patient cohorts, and to follow-up disease progression or disease responses to novel
therapies.  With  emerging  technologies,  that  is,  mass  spectrometry  and  nuclear
magnetic resonance applications to metabolomics and various software solutions of
bioinformatics, it has become possible to measure thousands of metabolites simulta‐
neously. These fascinating new techniques provide a powerful tool for setting scientific
hypotheses and linking cellular pathways to biological mechanism. This review focuses
on mass spectrometry-based metabolomics as a tool for iPSC research.
Keywords: iPS cell-derived neural cells, metabolomics, mass spectrometry, Alzheim‐
er’s disease, Parkinson’s disease
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1. Introduction
Stem cell reprogramming has provided a completely new way to explore human develop‐
ment and diseases. This novel technology is especially useful when investigating diseases in
which affected tissue are not easily accessible prior to autopsy. The central nervous system is a
good example of a tissue that falls into this category. Using induced pluripotent stem cells (iPSCs)
to model human brain diseases has remarkable potential to generate insights into understand‐
ing disease mechanisms and opening new avenues for the development of effective clinical
intervention. Importantly, iPSCs may allow for searching potential biomarkers of brain diseases,
especially neurodegenerative diseases which are well known to be diagnosed far too late to be
efficiently treated. Disease-specific iPSCs are now available from patients of several major
neurodegenerative diseases.
Metabolomics combines strategies to identify and quantify endogenous small molecules that
are products of biochemical reactions, and thereby to reveal connections between different
pathways that operate within a living cell. Nontargeted metabolite profiling has become a
powerful analytical tool to reveal molecular mechanism in various physiological and patho‐
physiological stages. Even though there are a lot of publications related to these techniques,
there are only a few reports combining iPSCs technologies and nontargeted metabolite
profiling.
In this chapter, we first describe the use of nervous system disease-specific iPSCs to model
human neurodegenerative diseases. Next, we summarize key metabolites from human cohort
studies of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Finally, the recent findings
in mass spectrometry-based nontargeted metabolite profiling are discussed to reveal the
details of cellular mechanism in iPS cell-derived neurons and astrocytes.
2. Human-induced pluripotent stem cells (iPSCs) in studies of nervous
system diseases
2.1. Application of iPSCs in neurodegenerative diseases
Chronic neurodegenerative diseases are characterized by the slow and progressive loss of
neuronal functions, which in turn results in memory loss, cognitive deficits, and/or motor
coordination impairment or even loss of motor functions. Neurodegenerative diseases, such
as AD, amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD), PD, and spinal
muscular atrophy (SMA), are typically of sporadic origin or are caused by very rare gene
mutations (Table 1). Although intensive efforts have been made, effective treatments for
neurodegenerative diseases have not been yet discovered.
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Disease Gene Cell type Phenotype References
Alzheimer’s
disease
APP, PS1, PS2,
sporadic
Cortical neurons Increased deposition of amyloid β; activated GSK-3β; endosomal
abnormalities; APP mutations increased total and pTau protein,
whereas PS1 mutations did not
[1–6]
Amyotropic
lateral sclerosis
SOD1, VAPB,
TDP43, FUS,
C9ORF72,
sporadic
Motor neurons,
astroglia
Reduced survival, cytoplasmic and nuclear protein aggregation,
altered expression in genes encoding cytoskeletal proteins,
neurofilament aggregation, mitochondrial defects, increased
oxidative stress, activation of ER and UPR
[7–16]
Huntington’s
disease
HTT Glutamatergic
neurons,
GABAergic
neurons, astrocytes
Reduced survival, neurite outgrowth and firing capacity, enhanced
lysosomal activity, changes in actin cytoskeleton, decreased cell-cell
adhesion properties, and decreased intracellular ATP, decreased
ATP/ADP ratios; increased susceptibility to stressors, vacuolation
phenotype of astrocytes
[17–23]
Parkinson’s
disease
LRRK2, GBA,
PINK1, SNCA,
PARKIN, sporadic
Dopaminergic
neurons
Reduced number of neurons and their branches, mitochondrial
dysfunction, elevated α-synuclein, reduced synthesis and release of
dopamine, increased MAOB expression, impaired autophagy,
increased susceptibility to stressors, activated ERK, impaired
intrinsic network activity, reduced GBA activity
[24–32]
Spinal muscular
atrophy
SMN1, CAG
repeats
Motor neurons Reduced number of neurons, abnormality in neurite outgrowth,
impaired clustering of AchR
[33–35]
AchR, acetylcholine receptor; APP, amyloid precursor protein; C9ORF72, chromosome 9 open reading frame 72; ER,
endoplasmic reticulum; ERK, extracellular signal-regulated kinases; FUS, fused in sarcoma; GBA, glucosidase beta
acid; GSK-3β, glycogen synthase kinase-3 beta; HTT, hungtintin; LRRK2, leucine-rich repeat kinase 2; MAOB,
monoamine oxidase B; PINK1, PTEN-induced putative kinase 1; PS1, presenilin 1; PS2, presenilin 2; SMN1, survival of
motor neuron 1; SNCA, alpha-synuclein; SOD1, superoxide dismutase; TDP43, transactive response DNA-binding
protein 43; UPR, unfolded protein response; VAPB, vesicle-associated protein B.
Table 1. Neurodegenerative diseases modeled with iPSCs.
Possible reasons for failing to develop efficient therapies include the lack of appropriate disease
models of human neurons and a limited understanding of the etiological and neurobiological
mechanisms of neurodegenerative diseases. Recent advances in PSC research have now
opened the path to the generation of iPSCs starting from somatic cells, thus offering an
unlimited source of patient-specific disease-relevant neuronal cells. By applying sophisticated
differentiation protocols, iPSCs can be directed to differentiate to functional neuronal sub‐
types, such as glutamatergic cortical neurons, striatal GABAergic neurons, midbrain dopami‐
nergic (DA) neurons, or motor neurons of the spinal ventral horn. Since patient-specific cells
are used to generate neuronal population, the resulting phenotype of these cells can be used
to model the pathology of neurons or other neural cells within the same individual.
2.1.1. Modeling AD with disease-specific iPSCs
The central nervous system has a limited capacity to regenerate after acute injuries or during
chronic degenerative diseases. Neurodegeneration is probably most studied and characterized
in AD and PD.
AD is the most prevalent age-related disorder characterized by dysfunction and deterioration
of neurons within the neocortex and limbic system, resulting in gradual progressive memory
loss and cognitive decline. More than 48 million patients are afflicted with AD worldwide. AD
is the most common cause of dementia and may contribute to 60–70% of the cases. There are
currently no medications for preventing the disease progression. Even though the pathogen‐
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esis of AD has been extensively studied during the last decades, the mechanisms underlying
the neuronal defects and synaptic damage in this disease are still unclear. Mutations in the
presenilin 1 (PS1), presenilin 2 (PS2), and the amyloid precursor protein (APP) genes account
for most of the familial early onset cases of AD by enhancing the production of pathological
amyloid beta (Aβ), especially Aβ42, which has a greater tendency to form fibrillary amyloid
deposits. The large amounts of Aβ accumulate and form senile plaques in the brains of AD
patients.
The “amyloid hypothesis” states that extracellular Aβ deposits are the cause of the disease [36].
This theory has been difficult to verify in living neurons of patients, using ordinary models
and technologies. Fortunately, iPSCs technology and the recent method‘s development toward
AD iPS cell-derived cortical neurons provides access to cell types that were previously
unobtainable [37]. Presenilin-1 (PS1) A246E and presenilin-2 (PS2) N141I iPSC-derived
neurons in conventional 2D cultures produced twice the normal level of highly toxic Aβ42 [1].
In one report, the Aβ accumulation was also seen in neuronal cells derived from sporadic AD
patient-derived iPSCs [2]. In addition to Aβ, the accumulation of phosphorylated Tau was
observed in neurons of sporadic AD patients, but not in iPS cell-derived neurons that had a
PS1 or PS2 gene mutation [2]. Moreover, cerebral neurons derived from iPSCs of APP-mutant
patients (E693D, V717L) and sporadic AD patients showed an accumulation of Aβ oligomers
associated with endoplasmic reticulum and increased oxidative stress [3]. Intracellular stress
and neuronal death were inhibited with the unsaturated fatty acid docosahexaenoic acid
(C22:6n3) in neurons derived from one patient carrying mutant APP and one patient with
sporadic AD. These findings point out a diversity of pathologies in AD and indicate the need
for individual treatment strategies. In line with this conclusion go also the results from a very
recent study where neurons derived from patients with various forms of AD differed in APP
processing [6]. While in iPSC models, APP mutations appeared to increase the levels of total
and phosphorylated Tau, PS1 mutations failed to do so. Finally, AD pathology was recapitu‐
lated in a single 3D human neural cell culture system where human neural progenitor cells
overexpressed mutant APP or both mutant APP and mutant PS1. These mutations induced
robust deposition of Aβ and exhibited high levels of pTau [4]. ApoE4 is the major known
genetic risk factor for sporadic AD. Defining the precise functions of ApoE that lead to AD
pathology is likely to allow for more specific therapeutic treatment. Combination of iPSC
technology and genome editing may shed light on the role of ApoE in AD.
In summary, disease-specific iPSCs have provided the field of neurodegeneration with an
exciting tool for research. Revealing the mechanisms underlying AD and other brain diseases
is essential for advancing our understanding of those disorders with the goal of finding
effective therapies that would restrain or stop disease progression.
2.1.2. Modeling PD with disease-specific iPS cells
PD is the third most common neurodegenerative disorder after AD and dementia with Lewy
bodies and affects approximately 1–2% of the population over 60. The pathology is character‐
ized by the progressive degeneration of dopaminergic (DA) neurons in the substantia nigra pars
compacta and by intracellular inclusions known as Lewy bodies [38]. The loss of DA neurons
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results in motor symptoms, including resting tremor, cogwheel rigidity, bradykinesia, and
later in the course of the disease, loss of postural reflexes. Despite extensive research, there is
no cure for this devastating disorder. The majority of PD cases are sporadic and of unknown
origin, with up to 10% of patients presenting with familial monogenetic forms of the disease.
Combination of genetic and environmental factors is likely to play an important role in the
pathogenesis of PD. Although monogenic forms of PD account for a small percentage of PD
cases, the most successful reports involving PD modeling to date utilize DA neurons from
patients with monogenetic mutations in which the gene mutation has been characterized
(Table 1). Understanding how mutations of these genes cause the degeneration of DA neurons
is critically important for the mechanistic studies as well as for the identification of disease-
modifying drugs. In human molecular genetic studies, at least 18 loci and 11 genes leading to
the development of PD have been identified. Mutations in SNCA, UCHL1, LRRK2, PINK1,
DJ-1, and ATP13A2 can lead to monogenic forms of PD [39]. Furthermore, mutations in genes
including those that code for SNCA, LRRK2, and GBA have been found to be risk factors for
sporadic PD [40], and in many cases people carrying these mutations will develop PD. Overall,
the most extensively studied PD-related genes are SNCA and LRRK2. DA neurons derived
from iPSCs of PD patients with triplication of the SNCA gene produced double the amount of
α-synuclein protein when compared with the normal controls [24]. Also, DA neurons bearing
the LRRK2 G2019S mutation showed an increased level of α-synuclein and greater oxidative
stress [25]. These diseased DA neurons also exhibit an increased number of autophagy
vacuoles and impaired synaptic and neuritic morphology [35]. In the latest study, gene
correction of LRRK2 G2019S mutation in iPSCs resulted in phenotypic rescue of differentiated
DA neurons [30].
In summary, studies of PD using iPSCs technology have shown the presence of PD-associated
abnormalities in mitochondrial function, autophagy/lysosomal pathway, axonal transport,
and neurite extension. These findings open up an opportunity to use iPSC-derived human
midbrain DA neurons in studies of disease mechanisms, biomarker search, and drug devel‐
opment, even in much larger scale.
3. Metabolomics
The metabolome of an organism refers to the complete set of endogenous and exogenous
molecules present in biological sample. Metabolite concentrations reflect the phenotype of
tissue or cells and provide insights into the biochemistries of the disease [41, 42]. There are two
general approaches used in metabolomics study; targeted and nontargeted metabolomics. The
targeted approach measures only a defined set of metabolites, whereas the nontargeted
profiling, or global approach, measures as many metabolites as possible [41, 43]. The nontar‐
geted metabolomics cover very wide concentration range of the metabolites present in the cells
(i.e., from millimolar (mM, 10−3 mol/L) to attomolar (aM, 10−18 mol/L)) with the different
chemical and structural diversities of compounds. Recent developments in mass spectrometry
(MS) and bioinformatics-related software solutions have enabled to measure thousands of
metabolites simultaneously from biological sample.
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MS is an analytical technique that sorts molecules as ions, based on their mass-to-charge (m/z)
ratio. As a detection method, MS provides the quantitation with extremely high selectivity and
sensitivity, reproducibility, and a wide dynamic range from highly complex biological samples
such as iPSC-derived neurons and astrocytes. In addition, MS has the ability to give a specific
information about molecular structure, which together with the above-mentioned qualities
makes MS the technique of choice for metabolomics [43, 44]. Biological samples with extreme
molecular complexity can be detected by MS combined with gas chromatography (GC) or
liquid chromatography (LC) [45–49]. In addition to chromatographic techniques, MS has been
combined to capillary electrophoresis (CE) and flow injection analysis (FIA) used in shotgun
lipidomics [45, 46].
Targeted approach measurements are hypothesis-driven and focus on one or more metabolic
pathways of interest [41]. A specified list of metabolites is measured by highly optimized
protocols in regard to sampling, sample preparation, and instrumental analysis of these
metabolic classes [52–54]. The most widely used MS technique for these types of analyses is
the triple quadrupole mass spectrometer in combination with atmospheric pressure ionization
techniques (i.e., electrospray ionization (ESI) and atmospheric pressure chemical ionization
(APCI) [43–55].
Nontargeted metabolite profiling aims to simultaneously measure as many metabolites as
possible from a biological specimen, in this case from iPSC-derived neurons or glia. These
studies are often hypothesis-generating, and therefore it is important to carefully construct an
experimental design that maximizes the number of metabolites detected and their quantitative
reproducibility [41]. The workflow of nontargeted metabolite profiling used in our laboratory
to study iPSC-derived neurons and astrocytes is presented in Figure 1. We adapted previously
published protocols to generate iPSC-derived mesencephalic dopaminergic neurons [56, 57]
and astrocytes [58]. To maximize the number of molecular features obtained from cell culture
samples, it is possible to optimize several steps in the nontargeted metabolite profiling
workflow (i.e., sample extraction, chromatographic separation, ionization, mass filtering, and
detection of metabolites) [42, 43, 55, 59, 60]. Samples are measured with ultra-high performance
liquid chromatography (UHPLC), combined with high accuracy and resolution mass spec‐
trometers with fast scanning capabilities, like the quadrupole time-of-flight (QTOF) mass
spectrometer [59, 61]. In our laboratory, two chromatographic separation techniques (i.e.,
reversed phase (RP) and hydrophilic interaction chromatography (HILIC)) are used to cover
both hydrophilic and hydrophobic metabolites. In addition, both ionization polarities (i.e.,
positive and negative) in ESI are employed to widen the coverage of metabolites present in
the sample. After data acquisition, the molecular features are extracted and the results
delivered for downstream univariate and multivariate statistical analyses. The identification
of metabolites is based on the comparison of the accurate mass and isotope information (i.e.,
ratios, abundances, and spacing), as well as product ion spectra (MS/MS) to metabolite
databases (e.g., the Human Metabolome Database (HMDB) and METLIN). This tentative
identification is subsequently confirmed by comparing tandem mass spectrometry (MS/MS)
data, together with chromatographic retention time with reference standards.
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Using nontargeted metabolite profiling, in concert with the iPSC technology, presents the new
opportunity to better understand the biological processes inside of a cell and extend our view
of AD and PD pathophysiology. In our hands, this technique provides thousands of molecular
Figure 1. The proposed workflow. The proposed workflow of the nontargeted metabolite profiling for iPS cell-derived
neurons and astrocytes. After data acquisition, the results are processed by bioinformatics software for peak-picking,
nonlinear retention time alignment, visualization, relative quantification, and statistical analysis. ESI(−), negative mode
electrospray ionization; ESI(+), positive mode electrospray ionization; HILIC, hydrophilic interaction chromatography;
RP, reversed phase.
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features from the neurons and astrocytes (unpublished data). In conclusion, MS-based
metabolite profiling has a central role in revealing the metabolic pathways in healthy and
disease-specific iPSCs.
3.1. Metabolomic profiling of AD and PD
Metabolomics is a powerful tool measuring the downstream products of the –omics cascade
that reflects genomic, transcriptomic, and proteomic changes in a given biological sample.
Metabolomics characterizes the endogenous small molecules and reveals connection between
different pathways within a living cell in health and disease [41]. More than 3000 metabolites
have been reported, but this number is not ultimate, as many metabolites need to be still
identified and characterized. Out of 3000 metabolites, approximately 550 metabolites are of
particular interest in studies of brain diseases [62]. Among the metabolites of interest are
obviously neurotransmitters, but it is especially phosphates and lipids that are likely to reveal
novel features of neurodegenerative diseases with the potential to help drug discovery or
identification of novel biomarkers for brain diseases.
Disease  Sample  Instrumentation  Key metabolites  Ref.
Alzheimer’s
disease
Brain
(post mortem) 
UPLC-QTOF-MS Unidentified metabolites [49]
CSF
(post mortem) 
HPLC-EC Up: methoxy-hydroxymandelate, 5-hydroxytryptophan,
methoxy-hydroxyphenylglycol, Down: alpha tocopherol, norepinephrine,
ascorbate, 3-methoxytyramine
[64]
CSF GC–MS
LC–MS/MS
Up: pyruvate, creatinine, cysteine,
tyrosine, serine, phenylalanine, methionine, cortisol,
dopamine Down: uridine
[45]
CSF CE–MS Up: choline, valine, serine
Down: carnitine
[51]
CSF HPLC-EC Up: 5-hydroxyindoleacetic acid,
methionine, xanthosine, vanillylmandelic acid, gluthatione Down: gluthatione/
methionine,
5-hydroxyindoleacetic acid/5-hydroxytryptophan
[65]
Plasma MDMS-SL Up: ceramide
down: sphingomyelin
[50]
Plasma UPLC-MS/
GCxGC-MS
Up: 2,4-dihydroxybutanoic acidDown: ether
phospholipids, phosphatidylcholines, sphingomyelins, sterols
[46]
Plasma LC–MS/MS
UPLC-QTOF-MS 
Down: serotonin, phenylalanine, proline, lysine, taurine,
phosphatidylcholine, acylcarnitine
[47]
Parkinson’s
disease
CSF
(post mortem) 
UHPLC-MS/MS
GS–MS
Up: 3-hydroxykynurenine down: oxidized glutathione, N-acetylated amino acids,
trimethylglycine, corticosteron
[48]
Plasma HPLC-EC Up: glutathione, 2-hydroxy-2-deoxyguanosine
Down: uric acid
[67]
Plasma HPLC-EC Down: hypoxanthine, uric acid, hypoxanthine/xanthosine,
xanthosine/xanthine, hypoxanthine/uric acid
[68]
CE–MS, capillary electrophoresis–mass spectrometry; CSF, cerebrospinal fluid; GC–MS, gas chromatography–mass
spectrometry; HPLC-EC, high-performance liquid chromatography electrochemical detector; LC–MS/MS, liquid
chromatography-tandem mass spectrometry; MDMS-SL, multidimensional mass spectrometry-based shotgun
lipidomics; UPLC-QTOF-MS, ultra-performance liquid chromatography quadrupole time-of-flight mass spectrometry.
Table 2. Summary of key metabolites from human cohort studies of AD and PD patients.
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Studies utilizing different analytical platforms have already identified several AD pathology-
related metabolites in cerebrospinal fluid (CSF) and plasma from human cohorts (Table 2).
Importantly, by using metabolomics set enrichment analyses, it is possible to identify and
quantify metabolite changes [63]. The changes of neurotransmitters (e.g., dopamine, adrena‐
line, and noradrenaline) are tightly linked to phenylalanine and tyrosine metabolism pathways
and have been found to be altered in CSF of AD patients [45]. While the decrease of noradre‐
naline may correlate with the severity of the disease [64], the increased levels of vanillylman‐
delic acid seem to correspond to a degradation of xanthine and dopamine [65]. The studies
using serum of AD patients have revealed the decrease in several lipid classes, especially
sphingomyelins [46, 50]. The most recent study followed elderly adults for 4 years, at a time
by which some from them had developed AD [47]. The authors identified 10 metabolite profile
features, phospholipids that play a role in integrity and functionality of cell membranes and
were predictive of the occurrence of mild cognitive impairment or AD within 2–3 year time
frame. The finding supported the link between dyslipidemia in AD and APOE4 variant as a
major risk allele for AD that leads to disruption in sphingolipid metabolism [66]. It is reason‐
able to assume that global metabolite profiling directly from the brain cells (i.e., iPSC-derived
material) of corresponding patients with AD or carrying APOE4 gene variant would tremen‐
dously increase the sensitivity of the method.
It is known that different areas of brain are affected during progression of neurodegenerative
diseases. The composition of metabolites in CSF reflects the neuronal integrity as well as the
underlying pathology of brain that leads to changes in brain metabolism. Studies from CSF of
postmortem PD patients have shown the activation of kynurenine pathway by increase of 3-
hydroxykynurenine concentration [48].
While 3-hydroxykynurenine contributes to oxidative stress, glutathione is known for its
antioxidant proprieties. The levels of glutathione were found to be increased in PD plasma
samples reinforcing the contribution of oxidative stress [67]. In the same study, the levels of
uric acid were negatively associated with PD progression. The aberrations in the purine
pathway that might appear upstream from uric acid have been studied in LRRK2 PD and
sporadic PD [68]. Based on the plasmatic changes of nine metabolites involved in purine
metabolism, the authors were able to predict whether the PD was secondary to LRRK2
mutation or of sporadic origin. A key perspective in metabolic phenotyping of brain diseases
like AD and PD depends on the metabolic features interpretation: a single metabolite is
unlikely to be a biomarker of a disease, while combinations of altered metabolites could form
a diagnostic metabolic signature of the disease.
3.2. Cell-type specific metabolomics
Nontargeted metabolite profiling so far has focused to predict diseases by measuring the
changes in specific metabolites in brain and CSF or systemically from plasma or urine.
Essentially, the next step would be to move to the study of cell-type specific metabolic
variations. iPS cell-derived neurons and astrocytes of AD and PD patients can be used to study
cell-type specific metabolites which could determine whether the brain pathology changes
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originate from one cell type or another. This approach will also provide insights into neuron/
glia cell co-metabolome and will help to refine more targeted treatments for those diseases.
The causes of AD and PD diseases suggest a combination of genetic and environmental factors,
with possible mechanisms ranging from mitochondrial dysfunction, oxidative stress, protein
aggregation, impaired protein degradation, dysregulated autophagy, and inflammation. So
far, there are only unpublished data available from one metabolome analysis of PARK2 iPS
cell-derived neurons briefly discussed in a review by Okano and Yamanaka [69]. The changes
seen in glycolytic pathways, the tricarboxylic acid cycle (TCA), and pentose phosphate
pathways suggest that mitochondria are the sites of dysfunctions in neurons harboring PARK2
mutation (H.O. unpublished data). Abnormalities in mitochondria were further confirmed by
morphology and impaired mitochondrial turnover (unpublished data). As mitochondria are
required for the energy demands of the brain cells including neurons, mitochondrial altera‐
tions can promote neuron degeneration. Mitochondrial complex I activity and its regulation
by transcriptional factors are both seen to be altered also in PD patients [70]. Reduced level of
mitochondrial α-ketoglutarate dehydrogenase, a rate-limiting enzyme in TCA cycle, was
reported in the brain of PD patients [71–73], suggesting the involvement of bioenergetics
defects as well reduced mitochondrial complex activity in PD pathology. The results from
postmitotic human dopaminergic neurons (DA) exposed to mitochondrial respiratory chain
inhibitor MPP+ (1-methyl-4-phenylpyridinium) are in line with those findings. Altogether, 190
metabolites have been found altered in MPP+-treated DA neurons [74]. In energy metabolism,
decreased levels of intracellular glucose leads to increase of pyruvate and lactate, while
consumption of phosphorylated creatine and accumulation of creatine suggest depletion of
the cellular energy accompanied by gradual increase of ADP, AMP, and adenine [74]. De‐
creased total intracellular ATP levels have also been found from fibroblast cells of PD patients
with mutations in LRRK2 accompanied with decreased mitochondrial membrane potential
[75]. Moreover, increase in methionine sulfoxide formation in MPP+-treated DA neurons
suggested an increase in oxidative stress and ROS production [74]. To better understand the
effects of oxidative stress pathways on cellular metabolism, we propose to apply a combined
strategy, consisting of nontargeted metabolite profiling together with gene expression analyses
to characterize DA neurons and astrocytes derived from iPSCs of PD patients, both sporadic
and familiar form. This will allow us to explore how the cells of interest generate reducing
potential to compensate oxidative stress and how this could be impaired in genetically
perturbed cells.
Several studies have suggested an important role of mitochondria also in the onset and
progression of AD [76]. The fact that mitochondria are prime targets for APP as well for Aβ [77]
has been underlined in studies of neuronal cells overexpressing APP and Aβ that leads to
abnormal mitochondrial dynamics via modulation of mitochondrial fission/fusion proteins
[78]. PET imaging has shown decreased levels of brain glucose metabolism in AD brain [79],
while another study has demonstrated decreased expression of genes involved in glucose
delivery, oxidative phosphorylation, and energy consumption in the brains of AD patients
[80]. Postmortem studies on AD brain and fibroblasts from AD patients have revealed changes
in TCA, pyruvate dehydrogenase, isocitrate dehydrogenase, and α-ketoglutarate dehydro‐
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genase [81–83]. In addition, the levels of ATP and activities of cytochrome oxidase were
reported to be decreased. Apart from direct mitochondrial respiratory chain defects, increased
autophagic degradation of mitochondria has also been reported [84].
While AD and PD pathology from diseased patients show late stages of these neurodegener‐
ative diseases, patient-specific derived iPSCs have a potential to model early presymptomatic
stage of AD and PD. In 2D cultures where the cells are grown in a monolayer, cell phenotype
might be amplified and seen much more earlier compared to the moment when patients are
diagnosed. On the other hand, 2D system lacks interaction between the other cells present
normally in human brain. In 3D culture models, cells interact with each other, but culture is
rather heterogeneous and compensation capability is higher than that in 2D culture. Therefore,
it would be necessary to study the metabolic changes in neurons and astrocytes first separately
as well as in co-culture, in order to understand the mechanisms behind the pathology. Genetic
background needs to be taken into account as well. Genetic correction of patient mutations or
introduction of mutation to healthy line allows validation of the role of mutations in the
observed phenotype.
4. Conclusions
In this review, we have described the current status of using disease-specific iPSCs to model
the onset and initial stages of neurodegenerative diseases such as AD and PD. Human iPSCs
improve disease modeling in previously inaccessible cells, such as neurons and astrocytes that
are the key cell types of the brain. Emerging evidence suggests that brain energy metabolism
goes beyond synthesis of neurotransmitters and that different pathways within neuronal cells
contribute to brain disorders. Combining the technologies of iPCS and untargeted metabolo‐
mics may provide a powerful tool to better understand the biological processes inside of cell.
In the future, brain metabolite profiles could be correlated to DNA polymorphisms, and
together with transcriptomics/proteomics data could provide a platform for new neuropro‐
tective strategies.
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